血浆 NfL、GFAP、淀粉样蛋白和 p-tau 作为帕金森病的预后生物标志物。
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease.
机构信息
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, P.Zzale Spedali Civili, 1, 25123, Brescia, Italy.
Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Hospital, Brescia, Italy.
出版信息
J Neurol. 2024 Dec;271(12):7537-7546. doi: 10.1007/s00415-024-12669-7. Epub 2024 Sep 9.
INTRODUCTION
The prognostic role of plasma neurofilament light chain (NfL), phospho-tau, beta-amyloid, and GFAP is still debated in Parkinson's disease (PD).
METHODS
Plasma p-tau181, p-tau231, Aβ1-40, Aβ1-42, GFAP, and NfL were measured by SIMOA in 136 PD with 2.9 + 1.7 years of follow-up and 76 controls. Differences in plasma levels between controls and PD and their correlation with clinical severity and progression rates were evaluated using linear regression analyses.
RESULTS
Patients exhibited similar distribution of plasma biomarkers but higher P-tau181, P-tau231 and lower Aβ1-42 compared with controls. NfL and GFAP correlated with baseline motor and non-motor severity measures. At follow-up, NfL emerged as the best predictor of progression with marginal effect of GFAP and p-tau181 adjusting for age, sex, disease duration, and baseline motor severity.
CONCLUSION
The present findings confirmed plasma NfL as best predictor of progression in PD, with a marginal role of p-tau181 and GFAP.
简介
在帕金森病（PD）中，血浆神经丝轻链（NfL）、磷酸化tau（p-tau）、β-淀粉样蛋白（Aβ）和 GFAP 的预后作用仍存在争议。
方法
采用 SIMOA 法检测 136 例 PD 患者（随访 2.9±1.7 年）和 76 名对照者的血浆 p-tau181、p-tau231、Aβ1-40、Aβ1-42、GFAP 和 NfL。采用线性回归分析评估对照组和 PD 患者血浆水平的差异及其与临床严重程度和进展率的相关性。
结果
患者的血浆生物标志物分布相似，但 p-tau181、p-tau231 较高，Aβ1-42 较低。NfL 和 GFAP 与基线运动和非运动严重程度测量值相关。在随访中，NfL 是进展的最佳预测因子，GFAP 和 p-tau181 的调整作用具有边缘意义，调整因素包括年龄、性别、病程和基线运动严重程度。
结论
本研究结果证实，血浆 NfL 是 PD 进展的最佳预测因子，p-tau181 和 GFAP 的作用具有边缘意义。
Zotero 插件